Calcium for Health & Longevity - Quick Reference Sheet

Calcium for Health & Longevity

Created on 07/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Calcium's value is real but narrower than its reputation. Its strongest benefit is skeletal: adequate intake slows age-related bone loss and, with vitamin D in deficient or frail people, reduces fractures. Food calcium also lowers kidney-stone risk, while supplements raise it and may unsettle heart safety. A food-first approach, filling only a measured gap, fits best. (Full Review)

Protocol

Target Intake
~1,000 mg/day
1,200 mg/day for women over 50 and men over 70; food-first, supplement only the shortfall
Dosing
500 mg or less per dose
Split larger daily amounts into two or more doses taken with meals
Form
Citrate or carbonate
Citrate for those on acid reducers or with low stomach acid; carbonate taken with food otherwise
Time to effect
Bone Density
1–2 years
Measurable improvement in bone mineral density
Hormone Normalization
Weeks
Parathyroid hormone normalizes within weeks
Perceived Effect
None
No perceptible short-term feeling from calcium

Benefits

Contraindications
  • Hypercalcemia
  • Primary hyperparathyroidism
  • Sarcoidosis or other granulomatous disease
  • History of calcium-containing kidney stones
  • Severe chronic kidney disease (eGFR below 30)
Key Interactions
  • Thyroid hormone (levothyroxine)
  • Bisphosphonates (alendronate, risedronate)
  • Tetracycline and fluoroquinolone antibiotics (doxycycline, ciprofloxacin)
  • Thiazide diuretics (hydrochlorothiazide)
  • Digoxin
  • Proton pump inhibitors (omeprazole) and other acid reducers
  • Iron and zinc supplements

Risk & Side Effects

  • High: Increased kidney stone risk from supplemental calcium; gastrointestinal effects
  • Medium: Cardiovascular events and myocardial infarction; hypercalcemia and milk-alkali syndrome; reduced absorption of iron and zinc
  • Low: Vascular calcification; prostate cancer
  • Speculative: Increased sessile serrated polyp risk with calcium plus vitamin D

Monitoring

Marker Target Why
Serum calcium (albumin-corrected) 8.8–10.0 mg/dL Detects hypercalcemia from over-supplementation
Ionized calcium 4.6–5.3 mg/dL Most accurate measure of biologically active calcium
25-hydroxyvitamin D 40–60 ng/mL Governs calcium absorption; low levels blunt benefit
Parathyroid hormone (PTH) 15–45 pg/mL (lower-normal ideal) Elevated levels signal inadequate calcium/vitamin D and ongoing bone loss
24-hour urinary calcium 100–250 mg/24 h Identifies hypercalciuria and kidney-stone risk
Phosphate 2.5–4.0 mg/dL Balances calcium metabolism; abnormal in kidney/parathyroid disease
Magnesium 2.0–2.4 mg/dL Needed for PTH and vitamin D function; competes with calcium
eGFR / creatinine eGFR >60 mL/min/1.73 m² Kidney function determines safety of supplementation
Coronary artery calcium (CAC) score 0 (Agatston units) Optional marker of arterial calcification for cardiovascular risk context

Cadence: Baseline before higher-dose or long-term use, at about 3 months after starting or changing dose, then every 6–12 months

Qualitative Assessment

  • Absence of new kidney-stone episodes or flank pain
  • No persistent constipation, bloating, nausea, or abdominal discomfort
  • Stable or improving bone-density scan results over 1–2 year intervals
  • No unexplained fatigue, excessive thirst, frequent urination, or confusion
  • Adequate energy and muscle function, with no cramps attributable to mineral imbalance